Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,216.00    38.00 (1.74%)
Bid:
2,220.00
Ask:
2,228.00
Spread: 8.00 (0.36%)
Market Cap: £1.47b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Senior Management Changes

4 Jan 2012 07:00

RNS Number : 9387U
Genus PLC
04 January 2012
 



 

For immediate release 4 January 2012

 

 

 

 

 

 

 

GENUS plc

("Genus" or "the Company")

 

Senior Management Changes

 

Genus, a leading global animal genetics company, announces two senior management changes within the Group.

 

Firstly, Genus is delighted to announce that Catherine Glickman will join the Company as Group Human Resources (HR) Director on January 5th 2012. Catherine will be leading the Group's talent management strategy as well as taking responsibility for engaging, equipping and investing in Genus employees to help the Group deliver its ambitious plans for growth. Catherine will become a member of the Genus Executive Leadership Team and will report directly to Karim Bitar, Chief Executive Officer.

 

Until recently, Catherine was the Head of HR at Tesco, one of the five largest global retailers with over 500,000 employees in 14 countries. During her 20 years at Tesco she was instrumental in developing the HR strategy that helped drive the retailer's strong growth and international expansion in recent years. Overall, she has over 25 years' experience in HR, within Tesco and beyond.

 

Secondly, Denny Funk Ph.D, the Company's Chief Scientific Officer, has also joined the Genus Executive Leadership Team. Dr. Funk will report directly to Karim Bitar, Chief Executive, and will have full responsibility for the Company's research & development (R&D) programme. This will ensure that R&D has a key and highly visible role as Genus pursues its ambitious plans for the future. Dr. Denny Funk was an Associate Professor at the University of Wisconsin-Madison before joining Genus in 1995.

 

Separately, Ian Biggs, formerly Head of Global Product and Business Strategy, has stepped down from his role to pursue other opportunities outside Genus. His primary responsibilities will be assumed by Dr. Denny Funk.

 

Karim Bitar, Chief Executive, commented:

 

 "I am delighted to announce the appointment of such a high calibre and experienced individual as Catherine to the role of Group HR Director. Catherine has been attracted and inspired by the Group's ambitious plans and is as enthusiastic as I am about the opportunities ahead. She will play a major role as she helps shape our talent management strategy."

 

"I would like thank Ian for the contribution he has made to Genus over the years and we wish him all the best for the future. Lastly, I am delighted that Denny has taken overall responsibility for R&D and I look forward to working with him closely as we ensure R&D plays a clear and consistent part in helping Genus meet evolving customer and market needs."

 

 

 

 

 

For further information please contact:

 

Genus plc Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

 

Buchanan Tel: 0207 466 5000

Charles Ryland, Suzanne Brocks, Catherine Breen

www.buchanan.uk.com 

 

 

This announcement is available on the Genus website, www.genusplc.com

 

 

About Genus

 

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality, and use these to supply the global dairy and meat supply chain.

 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

 

With headquarters in Basingstoke, England, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBJMRTMBJMBLT
Date   Source Headline
8th Mar 20221:13 pmRNSNotification of Major Holdings
24th Feb 20227:00 amRNSCollaboration between PIC and Olymel LP in Canada
24th Feb 20227:00 amRNSInterim Results
1st Feb 20224:57 pmRNSBlock listing Interim Review
4th Jan 20229:47 amRNSTotal Voting Rights
26th Nov 202110:18 amRNSDisclosure of Rights Attached to Equity Shares
24th Nov 20215:51 pmRNSDirector/PDMR Shareholding
24th Nov 20212:47 pmRNSResult of AGM
24th Nov 20212:30 pmRNSDirector/PDMR Shareholding
24th Nov 20217:00 amRNSAGM Trading Update
10th Nov 20212:28 pmRNSNotification of Major Holdings
15th Oct 20217:00 amRNSAnnual Report and Annual General Meeting
13th Oct 20215:56 pmRNSDirector/PDMR Shareholding
1st Oct 20213:58 pmRNSTotal Voting Rights
30th Sep 20219:59 amRNSDirector Declaration
29th Sep 20212:59 pmRNSNotification of Major Holdings
15th Sep 20214:45 pmRNSDirector/PDMR Shareholding
14th Sep 20214:32 pmRNSDirector/PDMR Shareholding
9th Sep 20217:00 amRNSPreliminary Results
1st Sep 20212:05 pmRNSTotal Voting Rights
2nd Aug 20214:00 pmRNSBlock listing Interim Review
2nd Aug 202110:09 amRNSTotal Voting Rights
1st Jul 20214:39 pmRNSTotal Voting Rights
28th Jun 20215:00 pmRNSPIC AND SERGAL ENTER INTO STRATEGIC RELATIONSHIP
22nd Jun 20217:00 amRNSCapital Markets Event & PRRSv Programme Update
14th Jun 20213:01 pmRNSNotification of Major Holdings
7th Jun 202110:42 amRNSApplication For Additional Listing
4th Jun 20214:38 pmRNSNotification of Major Holdings
17th May 20211:23 pmRNSNotification of Major Holdings
13th May 202110:50 amRNSDirector/PDMR Shareholding
9th Apr 20214:10 pmRNSDirector/PDMR Shareholding
6th Apr 20216:00 pmRNSDirector/PDMR Shareholding
1st Apr 20215:49 pmRNSTotal Voting Rights
31st Mar 20212:59 pmRNSDirector/PDMR Shareholding
22nd Mar 20217:00 amRNSBoard Changes
19th Mar 202112:20 pmRNSDirector/PDMR Shareholding
9th Mar 20215:41 pmRNSNotification of Major Holdings
3rd Mar 20215:19 pmRNSDirector/PDMR Shareholding
26th Feb 202112:39 pmRNSDirector/PDMR Shareholding
25th Feb 20217:00 amRNSInterim Results
1st Feb 202111:08 amRNSBlock listing Interim Review
1st Feb 202111:08 amRNSTotal Voting Rights
18th Jan 20217:00 amRNSTrading Update
2nd Dec 20205:44 pmRNSDirector/PDMR Shareholding
25th Nov 20201:13 pmRNSResult of AGM
25th Nov 20207:00 amRNSAGM Trading Update - Strong Performance Continues
11th Nov 20201:03 pmRNSNOTIFICATION OF MAJOR HOLDINGS
16th Oct 20208:00 amRNSAnnual Report and Annual General Meeting
1st Oct 20203:45 pmRNSTotal Voting Rights
25th Sep 20206:14 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.